- Tubular carcinoma:
- Is a distinct histopathologic subtype of breast cancer:
- Representing 1% to 2% of breast cancers diagnosed
- It is a distinct entity:
- From low-grade ductal carcinoma
- The literature continues to suggest that is has an excellent prognosis:
- With a very low likelihood of distant metastasis and excellent disease-free survival.
- In select patients:
- Adjuvant therapies may be omitted:
- However, there is a still a risk of axillary nodal metastasis:
- Sentinel lymph node biopsy is still recommended due to a 10% to 20% risk of lymphatic spread
- Despite this finding, there is likely to be only one node involved:
- This histopathologic subtype still conveys an excellent prognosis
- However, there is a still a risk of axillary nodal metastasis:
- Adjuvant therapies may be omitted:
- Tubular carcinoma is more likely to be identified on:
- Screening mammography and is more common in Caucasians than blacks
- Emerging data suggest that adjuvant systemic therapy can likely be safely omitted, although it should still be discussed with the multidisciplinary team
- Is a distinct histopathologic subtype of breast cancer:
- References
- Rakha EA, Lee AH, Evans AJ, et al: Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J Clin Oncol. 2010;28(1):99-104.
- Fedko MG, Scow JS, Shah SS, et al. Pure tubular carcinoma and axillary nodal metastases. Ann Surg Oncol. 2010;17(Suppl 3):338-342.
- Anderson WF, Chu KC, Chang S, Sherman ME. Comparison of age-specific incidence rate patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev. 2004;13(7): 1128-1135.
#Arrangoiz #CancerSurgeon #BreastSurgeon #SurgicalOncologist #BreastCancer #TubularBreastCancer #CASO #Miami #CenterforAdvancedSurgicalOncology
Rodrigo Arrangoiz MS, MD, FACS, FSSO 